[1]

Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020; ehaa612.

[2] Fumagalli S, Said SAM, Laroche C, et al. Age-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: The EORP-AF General Pilot Registry (EURObservational Research Programme-Atrial Fibrillation). JACC Clin Electrophysiol 2015; 1: 326−334. doi: 10.1016/j.jacep.2015.02.019 [3] Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093−100. doi: 10.1378/chest.10-0134 [4]

O'Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J 2015; 36: 3258−3264.

[5] Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011; 58: 395−401. doi: 10.1016/j.jacc.2011.03.031 [6] Shah SJ, Singer DE, Fang MC, et al. Net clinical benefit of oral anticoagulation among older adults with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2019; 12: e006212. doi: 10.1161/CIRCOUTCOMES.119.006212 [7] Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692−694. doi: 10.1111/j.1538-7836.2005.01204.x [8] Nieuwlaat R, Capucci A, Camm AJ, et al; European Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26: 2422−2434. doi: 10.1093/eurheartj/ehi505 [9] Zhu W, He W, Guo L, et al. The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol 2015; 38: 555−561. doi: 10.1002/clc.22435 [10] Apostolakis S, Lane DA, Guo Y, et al. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol 2012; 60: 861−867. doi: 10.1016/j.jacc.2012.06.019 [11] Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883−891. doi: 10.1056/NEJMoa1009638 [12] Gao X, Cai X, Yang Y, et al. Diagnostic accuracy of the HAS-BLED bleeding score in VKA- or DOAC-treated patients with atrial fibrillation: a systematic review and meta-analysis. Front Cardiovasc Med 2021; 8: 757087. doi: 10.3389/fcvm.2021.757087 [13] Bassand JP, Apenteng PN, Atar D, et al. GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke. Future Cardiol 2021; 17: 19−38. doi: 10.2217/fca-2020-0014 [14]

Chao TF, Liu CJ, Wang KL, et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol 2015; 65: 635–642.

[15] Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955−962. doi: 10.1016/S0140-6736(13)62343-0 [16] Schäfer A, Flierl U, Berliner D, Bauersachs J. Anticoagulants for stroke prevention in atrial fibrillation in elderly patients. Cardiovasc Drugs Ther 2020; 34: 555−568. doi: 10.1007/s10557-020-06981-3 [17] Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019; 380: 1509−1524. doi: 10.1056/NEJMoa1817083 [18] Bo M, Grisoglio E, Brunetti E, et al. Oral anticoagulant therapy for older patients with atrial fibrillation: a review of current evidence. Eur J Intern Med 2017; 41: 18−27. doi: 10.1016/j.ejim.2017.03.012 [19] Burgess S, Crown N, Louzada ML, et al. Clinical performance of bleeding risk scores for predicting major and clinically relevant non-major bleeding events in patients receiving warfarin. J Thromb Haemost 2013; 11: 1647−1654. doi: 10.1111/jth.12352 [20] Abdelhafiz AH, Wheeldon NM. Risk factors for bleeding during anticoagulation of atrial fibrillation in older and younger patients in clinical practice. Am J Geriatr Pharmacother 2008; 6: 1−11. doi: 10.1016/j.amjopharm.2008.03.005 [21]

Cobas Paz R, Raposeiras Roubín S, Abu Assi E, et al. Impact of anticoagulation in patients with dementia and atrial fibrillation. Results of the CardioCHUVI-FA registry. Rev Esp Cardiol (Engl Ed) 2020; 73: 877−884.

[22] Domínguez-Erquicia P, Raposeiras-Roubín S, Abbu-Assi E, et al. Incidence, predictors of bleeding and prognosis of bleeding in anticoagulated nonagenarian patients with atrial fibrillation. Int J Cardiol 2021; 327: 217−222. doi: 10.1016/j.ijcard.2020.11.023 [23] Proietti M, Romiti GF, Raparelli V, et al. Frailty prevalence and impact on outcomes in patients with atrial fibrillation: A systematic review and meta-analysis of 1, 187, 000 patients. Ageing Res Rev 2022; 79: 101652. doi: 10.1016/j.arr.2022.101652 [24] Ohta M, Hayashi K, Mori Y, et al. Impact of frailty on bleeding events related to anticoagulation therapy in patients with atrial fibrillation. Circ J 2021; 85: 235−242. doi: 10.1253/circj.CJ-20-0373